{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vasopressin
to a specific field?
Status:
Investigational
Source:
NCT02507284: Phase 2 Interventional Completed Irritable Mood
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Arginine vasotocin (Argiprestocin, AVT) is the non-mammalian homologue of arginine vasopressin (AVP) and was first synthesized as an AVP analogue. It was later found in non-mammalian vertebrates and induces similar physiological effects as AVP. AVT is considered the primary antidiuretic hormone. AVT functions to regulate expression of social and reproductive behaviors.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ataprost (also known as ONO-41483; OP-41483), an epoprostenol agonist, participated in phase II clinical trials in Japan for the treatment patients with heart failure and myocardial ischemia. However, these trials were discontinued.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
WAY 267464 dihydrochloride is a potent and selective agonist at the oxytocin receptor (OTR). WAY 267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin. WAY 267464 dose-dependently reduced anxiety on the four-plate test and prevented the deficits in prepulse inhibition induced by MK-801 or amphetamine. The ability of WAY 267464 to function as a V1AR antagonist may limit its potential therapeutic use in humans, as it would conceivably prevent the improvements in social behavior and social cognition that may be assumed to arise from a primary OTR agonist action.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
TC OT 39 was developed as potent non-peptide oxytocin receptor partial agonist and V2 vasopressin receptor agonist. Also was a V1a vasopressin receptor antagonist.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
